Site logo
Pharmaville Logo
    • Featured
    • Cornerstone Life Science Locations
    • Home
    • Locations
    • Events
    • Articles
      • Featured Editorial & Interviews
      • News and Insights
      • Xtalks Clinical Edge Magazine
    • More
      • Add or Update a Listing
      • About Pharmaville
      • Visit Xtalks
      • Contact
      • Terms of Use
      • Privacy Notice
    Add or Enhance a Listing
    Sign in or Register
    Add or Enhance a Listing
    Listing cover image

    USA

    • Claim listing
    • Location Details
    • Related Events
    • prev
    • next
    • Contact Us
    • Bookmark
    • Share
    • Claim listing
    • prev
    • next
    Description

    The United States remains the global epicenter of the life sciences ecosystem, driven by an unparalleled synergy between biotechnology innovation, pharmaceutical R&D and academic research excellence.

    Renowned for its robust venture capital landscape and high-density biotech clusters in hubs like Boston, San Francisco and San Diego, the USA leads the world in the commercialization of breakthrough therapies and orphan drugs.

    The nation's healthcare innovation is currently defined by the rapid integration of generative AI and precision medicine, which are transforming clinical trial efficiency and patient outcomes.

    In the medical device sector, US companies are pioneers in digital health, wearable technology and robotic-assisted surgery, supported by a sophisticated regulatory framework.

    Furthermore, the country's world-class research universities and the National Institutes of Health (NIH) provide a foundational pipeline for early-stage discovery in genomics, immunology and cell and gene therapy. As a leader in biomanufacturing and specialty pharmacy, the USA continues to attract significant foreign direct investment from global players seeking to access its high-value market. This dynamic environment is further bolstered by a shift toward value-based care and decentralized clinical trials, ensuring the US remains at the forefront of the global life sciences industry.

    Featured Editorial
    featured editorial
    Claim Your Profile to Receive a 1500-word Editorial Article

    Pharmaville offers locations the opportunity to be featured in an in-depth interview that highlights their unique strengths and advantages. These interviews showcase areas such as research expertise, clinical trial capacity, manufacturing infrastructure, and investment opportunities, and are published directly on the Pharmaville platform. This helps regions share their story with a global life science audience and position themselves as leading destinations for innovation and growth.

    Regions
    • United States
    • North America
    Healthcare and Research Infrastructure

    The US healthcare system is largely a mix of private and public provision. In 2020, total healthcare spending was about $4.1 trillion.

    The US leads globally in research infrastructure. In 2023, the National Institutes of Health (NIH) had a budget of around $48 billion, making it the largest single public funder of biomedical and behavioral research globally. Under the National NIH budget proposals of the Donald Trump administration, the agency's funding was targeted for deep cuts, with plans including a reduction of approximately 40% (around $18 billion) in the FY 2026 budget. In addition, the NIH cancelled or froze more than $2 billion in grants by early 2025 and cut indirect cost reimbursement rates for institutions from roughly 27% to 30%, down to 15%.

    The US hosts several powerhouse life sciences research centers driving innovation. At the federal core is the NIH in Bethesda, Maryland, a 27-institute biomedical engine that invests tens of billions annually across areas from genomics and neuroscience to infectious disease. In Boston, Massachusetts General Hospital and Brigham and Women's Hospital, both Harvard-affiliated, run two of the world's largest hospital-based research programs. Houston's MD Anderson Cancer Center is a leader in oncology research, while Oak Ridge National Laboratory contributes at the interface of biology, computation and biomanufacturing, leveraging supercomputing for bioenergy and systems biology.

    Gallery
    Government and Public Research Funding

    The NIH awarded approximately $36.94 billion in extramural research funding in FY24, supporting around 407,782 jobs and $94.58 billion in economic activity.

    In 2021, business funding accounted for about 75% of US R&D expenditures, while federal government funding fell to around 19%.

    Investment and Financing

    US medical and health-R&D investment reached $245.1 billion in 2020, of which industry provided around 66% (approximately $161.8 billion) and federal government around 25% (approximately $61.5 billion).

    Industry Presence

    The US houses thousands of pharmaceutical, biotech and medtech firms. There are more than 2,500 active pharmaceutical manufacturers in the country that employ approximately 381,202 workers. The US pharmaceutical market size had an estimated value of $634.32 billion in 2024, with a forecasted CAGR of 5.72% from 2025 to 2030 to reach $883.97 billion by 2030. The US is home to the world's largest concentration of pharmaceutical, biotechnology and medical device companies, representing a powerhouse of R&D, manufacturing and commercialization capacity. Major players such as Pfizer, Johnson & Johnson, Merck & Co., Eli Lilly, Amgen, Bristol Myers Squibb and AbbVie all maintain extensive headquarters or large-scale research and production operations across the country. Global companies like Novartis, Roche, Sanofi and AstraZeneca also operate significant US facilities for R&D and manufacturing. The US accounts for roughly 45% of global pharmaceutical sales and continues to attract the majority of global biotech venture capital investment. Industry clusters in Boston-Cambridge, San Francisco Bay Area, San Diego and Research Triangle Park drive much of this innovation, supported by nearby academic and clinical research hubs.

    Big Medtech Presence

    The US digital health market was estimated at $79.1 billion in 2024, and is projected to grow to around $248.1 billion by 2034. The medtech industry accounts for 40% of the global medtech market. The industry employs about 519,000 people in the US.

    Active Clinical Studies

    There are over 35,000 clinical studies underway in the US.

    Location
    • Washington, DC, United States

      Get Directions
    Related Events
    No Upcoming or Recorded Events Available
    Categories
    • Cornerstone Life Science Locations
    Tags
    • STEM Innovation
    Videos
    Listing image
    Economic Contribution

    Healthcare spending in the US totals over $4 trillion annually. The life sciences sector (including pharma, biotech, medtech) contributes significantly to employment, exports and innovation, though a precise single GDP figure for the sector is less often cited in public data.
    The US bioscience industry had a total economic output of more than $3.2 trillion in 2023, and employed over 2 million people at almost 150,000 business establishments, with indirect support for nearly 8 million additional jobs. The biopharmaceutical industry's direct value added has been estimated at roughly 1.6% of US GDP and has shown sustained growth in employment and production. In 2021, labor income in the US biopharma industry was nearly $54 billion, and the industry supports wages at a significant premium compared to the broader manufacturing sector.

    Life Science Workforce

    Employment in US life sciences reached a record 2.1 million in March 2025.

    Laboratory and Manufacturing Space

    The US maintains extensive life-sciences manufacturing and R&D infrastructure. The US research ecosystem performs around 78 % of national R&D in business-dominated sectors. Many major pharma companies are committing multi-billion-dollar investments in US manufacturing capacity. This includes a planned $50 billion investment by Roche over five years.

    The US lab market alone currently totals approximately 200 million ft² of space. Of that total, major clusters such as Boston-Cambridge, San Francisco Bay Area and San Diego each account for tens of millions of square feet of lab inventory. In the biomanufacturing domain, while exact national totals are harder to pin down, industry sources suggest bioproduction facilities and pilot-scale plants add tens of millions of additional square feet. Nationwide, life sciences construction activity has reached its peak, though ongoing projects in select cities are expected to keep vacancy rates elevated. Between 2022 and 2024, more than 43 million ft² of new lab and life sciences space came online across major US markets, including nearly 15 million ft2 added in 2024 alone.

    Talent, Innovation and IP

    The US remains a global leader in R&D intensity (around 3.5% of GDP in 2021). Business continues to swallow much of the R&D share (about 78% in recent years).

    Website

    Claim Profile to Update Website

    Contact

    Claim Profile to Update Contact Information

    Links

    Claim Your Profile to Add Related Links

    Downloadables

    Claim Your Profile to add downloadable documentation

    References

    https://pharmaville.com/wp-content/uploads/2026/02/Pharmaville-USA-references.pdf

    Related Event
    No Upcoming or Recorded Events Available

    You May Also Be Interested In

    San Francisco, California Verified listing

    Featured
    • Biopharma Hub
    • Add to comparison

    Ontario

    • Regenerative Medicine & Cell Therapy
    • Add to comparison

    Newfoundland and Labrador

    • Population Genetics & Real-World Evidence
    • Add to comparison
    • Terms of Use
    • Privacy Notice

    © Honeycomb Worldwide Inc.

    Cart

      • Featured
      • Cornerstone Life Science Locations
      • Facebook
      • LinkedIn